Drugs / HS-10561
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06864507 | Mar 2025 → Sep 2026 overdue | chronic idiopathic urticaria | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-25 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA RECEIVED APPROVAL FROM NMPA FOR CLINICAL TRIAL OF HS-10561, A SMALL MOLECULE BTK INHIBITOR FOR CHRONIC SPONTANEOUS URTICARIA hspharm.com ↗
HS-10561 capsules, which is jointly developed by the Group and in collaboration with Guangzhou Lupeng Pharmaceutical Co., Ltd. * (廣州麓鵬製藥有限公司), has obtained clinical trial approval by the National Medical Products Administration (NMPA) of China |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-25 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | HANSOH PHARMA RECEIVED APPROVAL FROM NMPA FOR CLINICAL TRIAL OF HS-10561, A SMALL MOLECULE BTK INHIBITOR FOR CHRONIC SPONTANEOUS URTICARIA hspharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10561 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06864507 ↗ |
| Route | Oral | “HS-10561 orally” NCT06864507 ↗ |